K Pro benefits from 10 years worth of AI tools for biology
Owkin’s AI tools are domain-specific
Owkin's AI tools are the accumulated scientific intelligence of 10 years of biopharma research. They are proprietary models built on unique patient data and designed to be called by K Pro to solve specific user queries.
Each model is backed by peer-reviewed publication or pre-print and validated on external datasets.
Owkin’s AI Tools
Tissue intelligence
Extract cellular, immune, & inflammatory signals from standard pathology slides.
Histology is the most widely available data in oncology. But for decades it's been read by eye, with all the variability that implies.
Owkin's AI extracts precise, reproducible, quantitative biology from H&E slides: cell populations, immune structures, molecular subtypes, and inflammatory states that previously required expensive assays, expert annotation, or both. This is biological measurement at scale.
Molecular profiling
Infer spatial & multi-omic biology from routine data, reducing expensive sequencing.
Spatial transcriptomics, single-cell sequencing, and bulk RNA-seq offer unprecedented biological resolution — but at a cost, complexity, and scale that makes routine use in clinical trials impractical.
Owkin's molecular profiling tools close this gap: predicting molecular-level biology from data that already exists, integrating multi-omic signals, and mapping how cells communicate within the tumor microenvironment.
Clinical intelligence
Translate biology into clinical trial decisions via stratification & response prediction.
Translating biological insight into clinical decisions — who responds, who progresses, how to design a trial — is where drug development either accelerates or stalls.
Owkin's clinical intelligence tools bridge this gap, combining AI-powered patient stratification, drug sensitivity prediction, and federated analysis of external data to de-risk and accelerate development programs.
Disease-specific models
Validated, disease-specific AI tools & 20+ tool portfolio across oncology biomarkers.
This is a portfolio of tools spanning biomarker discovery, survival prediction, and molecular subtyping, each anchored to a specific disease and a specific decision.
From mesothelioma diagnosis to FGFR3 detection in bladder cancer, these are not prototypes: they are proven models, ready to apply to real oncology problems.
Ready to get started?
Discover how K Pro can transform your drug discovery and development. Connect with our team to explore how we can support your specific needs.
